In this article, we will discuss Duvelisib (Dosage Overview). So, let’s get started.
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Duvelisib is indicated for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies.
1.2 Follicular Lymphoma (FL)
Duvelisib is indicated for the treatment of adult patients with relapsed or refractory FL after at least two prior systemic therapies.
The recommended dose of Duvelisib is 25 mg administered as oral capsules twice daily (BID) with or without food. A cycle consists of 28 days. The capsules should be swallowed whole.
Advise patients not to open, break, or chew the capsules.
Advise patients that if a dose is missed by fewer than 6 hours, to take the missed dose right away and take the next dose as usual. If a dose is missed by more than 6 hours, advise patients to wait and take the next dose at the usual time.
Provide prophylaxis for Pneumocystis jirovecii (PJP) during treatment with Duvelisib.
Following completion of Duvelisib treatment, continue PJP prophylaxis until the absolute CD4+ T cell count is greater than 200 cells/µL. Withhold Duvelisib in patients with suspected PJP of any grade, and discontinue if PJP is confirmed.
Consider prophylactic antivirals during Duvelisib treatment to prevent cytomegalovirus (CMV) infection including CMV reactivation.